Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no direct dose-for-dose equivalence between Wegovy (semaglutide) and Mounjaro (tirzepatide). They act on different receptors, produce different weight-loss profiles across different dose ranges, and no published clinical table maps one to the other. What trial evidence does suggest is that 7.5mg Mounjaro sits in the mid-range of tirzepatide's licensed schedule, and that semaglutide's 1.7mg or 2.4mg doses represent broadly comparable stages of treatment — though individual response varies considerably. These are prescription-only medicines; a GPhC-registered prescriber at our clinical team can review your full history before any switch or comparison is made.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide and semaglutide work differently at a receptor level. Semaglutide activates the GLP-1 receptor alone, slowing gastric emptying and reducing appetite through that single pathway. Tirzepatide activates both GLP-1 and GIP receptors, which appears to produce a stronger appetite-suppressing signal in many people, at least at the higher end of its licensed dose range.
Because the drugs operate through different mechanisms, their milligram figures are not on the same scale. 7.5mg of tirzepatide does not mean the same thing pharmacologically as 7.5mg of anything else. The numbers refer to the quantity of the respective active molecule delivered, not to a shared unit of clinical effect. Searching for the equivalent dose from Mounjaro to Wegovy is therefore a question that medicine cannot answer with a simple table.
What we can do is look at where each drug sits within its own licensed escalation, and what the trial data shows at those stages.
Mounjaro's licensed UK schedule starts at 2.5mg (a tolerability dose) and can be titrated in roughly four-week steps up to 15mg. The 7.5mg dose is the midpoint of that progression. In SURMOUNT-1, the landmark phase 3 trial published in the New England Journal of Medicine, participants randomised to 7.5mg saw average weight reductions of around 14.4% over 72 weeks, substantially more than placebo, and a clinically meaningful result, though lower than the approximately 20–21% seen at the 15mg dose. That gives 7.5mg a reasonable evidence anchor.
NICE's appraisal of tirzepatide, TA1026, notes that higher doses generally produce greater average weight loss, and that the decision to stay at or escalate beyond a given dose belongs to the prescriber reviewing the individual patient's progress and tolerance.
The comparison table below uses published trial data only.
| Medicine | Dose stage | Position in schedule | Avg weight loss (trial) | Trial / Source |
|---|---|---|---|---|
| Mounjaro (tirzepatide) | 7.5mg weekly | Mid-range (step 3 of 6) | ~14.4% | SURMOUNT-1, NEJM 2022 |
| Wegovy (semaglutide) | 1.7mg weekly | Penultimate maintenance | Not separately reported at 1.7mg | STEP 1, NEJM 2021 |
| Wegovy (semaglutide) | 2.4mg weekly | Standard maintenance | ~15% | STEP 1, NEJM 2021 |
| Wegovy (semaglutide) | 7.2mg weekly | Higher maintenance (approved Apr 2026) | ~20.7% | MHRA approval, Apr 2026 |
If forced to draw a rough parallel by average weight loss, the 7.5mg Mounjaro result (~14.4%) sits closest to Wegovy at its standard 2.4mg maintenance dose (~15%), and we've looked in detail at how 7.5mg Mounjaro compares to Wegovy for anyone who wants to explore that further. But that framing can mislead: trial populations differ, duration differs, and individual variation in response is substantial either way. For a fuller look at the Mounjaro equivalent to Wegovy 2.4mg, we've covered that comparison separately.
Switching between these two medicines is not as simple as matching numbers on a conversion chart. A prescriber will consider how long someone has been on their current dose, what side effects they've experienced, whether the current drug was producing adequate progress, any contraindications specific to the new medicine, and the patient's own preference about injection mechanism and routine.
Oral semaglutide also now exists as a licensed UK option (the Wegovy tablet, approved by the MHRA in June 2026) which changes the conversation for people who would prefer not to inject. That's a separate clinical discussion rather than a dose-equivalence question, and if you're trying to work out what dose of Wegovy is equivalent to 7.5mg Mounjaro, we've addressed that question directly in a dedicated guide. You can read more about how Wegovy and Mounjaro compare overall on a different basis.
One practical thing you can do before any consultation: write down your current dose, how long you've been on it, and what your most recent weight reading is. That takes about a minute and gives a prescriber the starting point they need to make a meaningful recommendation.
The question of dose conversion between Mounjaro and Wegovy comes up regularly, and our prescribers don't approach it with a lookup table. They approach it as a clinical review. Which medicine suits you (and at what dose) is a decision made with your full history in view, not from a comparison chart alone. Start your free consultation and a GPhC-registered prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.